ArticleHeliyon2024

Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment.

Tero Ylisaukko-Oja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.